Cure8 research brief
The review compiles trial and real-world safety data for upadacitinib in IBD and highlights monitoring needs and infection risks (notably herpes zoster), which are directly relevant when choosing or managing JAK inhibitor therapy.
Adults with ulcerative colitis or Crohn's disease considering or receiving JAK inhibitors, gastroenterologists and prescribing clinicians, and IBD researchers tracking drug safety.
This paper is a systematic review (2015–2025) that pooled data from phase II/III trials, real-world evidence, and pharmacovigilance databases (FAERS, EudraVigilance) to summarize safety signals for upadacitinib in UC and CD.
The review reports commonly observed adverse events such as upper respiratory infections, acne, and transient laboratory abnormalities (increased CPK and liver enzymes). Herpes zoster (shingles) is highlighted as the most notable class-specific risk for JAK inhibitors.
Because upadacitinib acts systemically, the authors emphasize screening for infections before starting therapy and routine laboratory monitoring (blood counts, lipids, liver enzymes) while on treatment.
Structured-content depth: abstract — the supplied text is a review abstract from Acta Poloniae Pharmaceutica summarizing methods and safety findings. It does not present new patient-level trial results. class-wide JAK safety considerations (infection risk, lab monitoring) are emphasized; consult treating clinicians for personalized decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
